Equity
Total Liabilities & Equity
Gilead Sciences Total Liabilities & Equity decreased by 4.7% to $56.28B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 0.3%, from $56.43B to $56.28B. Over 5 years (FY 2020 to FY 2025), Total Liabilities & Equity shows a downward trend with a -2.9% CAGR.
Analysis
StatementBalance Sheet Statement
SectionEquity
CategoryOther
SignalContext dependent
VolatilityStable
First reportedQ4 2014
Last reportedQ1 2026May 7, 2026
How to read this metric
Growth in this figure indicates an expansion of the company's asset base, funded either through debt or equity issuance.
Detailed definition
This is the sum of all liabilities and stockholders' equity, which must equal the total assets of the company according...
Peer comparison
Used as a baseline for calculating leverage ratios and assessing the scale of the company's operations.
Metric ID:
total_liabilities_and_equityHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $67.98B | $67.10B | $67.95B | $63.08B | $62.87B | $62.56B | $63.17B | $61.88B | $62.34B | $62.37B | $62.13B | $56.29B | $53.58B | $54.53B | $59.00B | $56.43B | $55.72B | $58.53B | $59.02B | $56.28B |
| QoQ Change | — | -1.3% | +1.3% | -7.2% | -0.3% | -0.5% | +1.0% | -2.0% | +0.7% | +0.1% | -0.4% | -9.4% | -4.8% | +1.8% | +8.2% | -4.3% | -1.3% | +5.0% | +0.8% | -4.7% |
| YoY Change | — | — | — | — | -7.5% | -6.8% | -7.0% | -1.9% | -0.8% | -0.3% | -1.7% | -9.0% | -14.0% | -12.6% | -5.0% | +0.3% | +4.0% | +7.4% | +0.0% | -0.3% |
Range$53.58B – $67.98B
CAGR-3.9%
Avg YoY Growth-3.5%
Median YoY Growth-1.8%
Total Liabilities & Equity at Other Companies
Frequently Asked Questions
- What is Gilead Sciences's total liabilities & equity?
- Gilead Sciences (GILD) reported total liabilities & equity of $56.28B in Q1 2026.
- How has Gilead Sciences's total liabilities & equity changed year-over-year?
- Gilead Sciences's total liabilities & equity decreased by 0.3% year-over-year, from $56.43B to $56.28B.
- What is the long-term trend for Gilead Sciences's total liabilities & equity?
- Over 5 years (2020 to 2025), Gilead Sciences's total liabilities & equity has grown at a -2.9% compound annual growth rate (CAGR), from $68.41B to $59.02B.
- What does total liabilities & equity mean?
- The total value of all company funding sources, which must equal the total value of all company assets.